Unique Coronary Liquid Biopsy Platform

OPPORTUNITY SUMMARY

A New Paradigm in Cardiovascular Risk Management

Coronary artery

disease 540m

Coronary Artery Disease is the single biggest killer globally

Cardiologists will use coronary biomarkers to predict patients’ risk of future events

How do we assess risk now? How will we assess risk in 5 years?

Pharma will utilise biomarker data to de-risk next-generation CVD pipeline therapies

Now: patent expiry & late-stage pipeline failures

Future: mechanistic biomarker data de-risks trials

≠

Committed to changing the current SOC in the diagnosis, prevention, and treatment of CAD

ü  Iden%fyingplaque-basedinflammatorybiomarkers

ü  Developingbespokeassays

ü  Linkingbiomarkerstoclinicaloutcomes

ü  DrivingtheuseofPlaqueTecassaysanddatatodevelopnewCADtherapies

2008

2010

2012

2014

2016

2017

PlaqueTec is pioneering a biomarker-based approach to transforming CAD care

LiquidBiopsySystem(LBS)prototypedeveloped

FirstLBSclinicaltrial

Launchedfirstin-humanstudies

ReceivedCEMark

Firstbiomarkerdatapresented

DatapublishedinJACC,BasictoTransla%onalScience(December)

What we’ve done Where we’re headed

Location of plaque in artery Plaque-derived biomarkers trapped in boundary layer

LBS tracks over guidewire Local biomarker release

Catheter takes seconds to position & deploy in artery

Samples downstream will contain plaque-related biomarkers

Differences (or gradients) detected will identify plaque-specific biomarkers

‘Baffles’ disrupt boundary layer; simultaneous sampling at 4 points

» Full video animation at www.plaquetec.com «

Disruptive technology that allows liquid biopsy at the site of coronary plaque

PlaqueTec Platform

Liquid Biopsy System (LBS)

Central Laboratory Tests

Predictors of outcome

Functional database

DEVICE DISEASE ACTIVITY ASSAYS

PROGNOSTIC DATA

RESEARCH PORTAL

A platform approach to transform CAD diagnosis and management

West NEJ, et al. J Am Coll Cardiol Basic Trans Science. 2017; 2: 646-54.

Proven presence of gradients of CAD inflammatory biomarkers

PlaqueTec Liquid Biopsy, a routine intervention to optimise the personalised

care of patients with coronary artery disease

Renewed momentum in exploring the residual risk of patients living with CVD

The academic community is looking for new approaches to personalised diagnostics and tailored interventions

The new PlaqueTec catheter will be ready for clinical use in Q4 2018

New team and leadership focused on science, medicine and commercialisation

New capital will secure the bridge to significant value inflection as data drives adoption of the catheter globally and unlocks strategic partnerships

Summary

PlaqueTec Ltd The Cardiothoracic Bioincubator

Papworth Hospital, Papworth Everard Cambridge CB23 3RE, United Kingdom

A new frontier in the treatment of cardiovascular disease